Abstract
Ion channels are membrane proteins involved in almost all physiological processes, including neurotransmission, muscle contraction, pace-making activity, secretion, electrolyte and water balance, immune response, and cell proliferation. Due to their broad distribution in human body and physiological roles, ion channels are attractive targets for drug discovery and safety pharmacology. Over the years ion channels have been associated to many genetic diseases (“channelopathies”). For most of these diseases the therapy is mainly empirical and symptomatic, often limited by lack of efficacy and tolerability for a number of patients. The search for the development of new and more specific therapeutic approaches is therefore strongly pursued. At the same time acquired channelopathies or dangerous side effects (such as proarrhythmic risk) can develop as a consequence of drugs unexpectedly targeting ion channels. Several noncardiovascular drugs are known to block cardiac ion channels, leading to potentially fatal delayed ventricular repolarization. Thus, the search of reliable preclinical cardiac safety testing in early stage of drug discovery is mandatory. To fulfill these needs, both ion channels drug discovery and toxicology strategies are evolving toward comprehensive research approaches integrating ad hoc designed in silico predictions and experimental studies for a more reliable and quick translation of results to the clinic side.
Here we discuss two examples of how the combination of in silico methods and patch clamp experiments can help addressing drug discovery and safety issues regarding ion channels.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Imbrici P, Liantonio A, Camerino GM et al (2016) Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol 7:121
Catterall WA, Swanson TM (2015) Structural basis for pharmacology of voltage-gated sodium and calcium channels. Mol Pharmacol 88:141–150
Imbrici P, Altamura C, Camerino GM et al (2016) Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies. FASEB J 30:3285–3295
Imbrici P, Conte D, Liantonio A (2017) Paving the way for Bartter syndrome type 3 drug discovery: a hope from basic research. J Physiol 595:5403–5404
Jentsch TJ (2015) Discovery of CLC transport proteins: cloning, structure, function and pathophysiology. J Physiol 593:4091–4109
Verkman AS, Galietta LJV (2009) Chloride channels as drug targets. Nat Rev Drug Discov 8:153–171
Huang H, Pugsley MK, Fermini B, Curtis MJ, Koerner J, Accardi M, Authier S (2017) Cardiac voltage-gated ion channels in safety pharmacology: review of the landscape leading to the CiPA initiative. J Pharmacol Toxicol Methods 87:11–23
Lynch JJ, Van Vleet TR, Mittelstadt SW, Blomme EAG (2017) Potential functional and pathological side effects related to off-target pharmacological activity. J Pharmacol Toxicol Methods 87:108–126
Accardi MV, Pugsley MK, Forster R, Troncy E, Huang H, Authier S (2016) The emerging role of in vitro electrophysiological methods in CNS safety pharmacology. J Pharmacol Toxicol Methods 81:47–59
Tikhonov DB, Zhorov BS (2012) Architecture and pore block of eukaryotic voltage-gated sodium channels in view of NavAb bacterial sodium channel structure. Mol Pharmacol 82:97–104
Feng L, Campbell EB, Hsiung Y, MacKinnon R (2010) Structure of a eukaryotic CLC transporter defines an intermediate state in the transport cycle. Science 330:635–641
Zou B (2015) Ion channel profiling to advance drug discovery and development. Drug Discov Today Technol 18:18–23
Skalova S, Svadlakova T, Shaikh Qureshi WM, Dev K, Mokry J (2015) Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine. Int J Mol Sci 16:4043–4067
Jan LY, Jan YN (2012) Voltage-gated potassium channels and the diversity of electrical signalling. J Physiol 590:2591–2599
Zamponi GW, Striessnig J, Koschak A, Dolphin AC (2015) The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 67:821–870
Gintant G, Sager PT, Stockbridge N (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15:457–471
Gintant G, Fermini B, Stockbridge N, Strauss D (2017) The evolving roles of human iPSC-derived cardiomyocytes in drug safety and discovery. Cell Stem Cell 21:14–17
Lavecchia A, Cerchia C (2016) In silico methods to address polypharmacology: current status, applications and future perspectives. Drug Discov Today 21:288–298
Langer T, Wermuth C-G (2012) Selective optimization of side activities (SOSA): a promising way for drug discovery. In: Peters J-U (ed) Polypharmacology in drug discovery, 1st edn. John Wiley & Sons, Inc., New York, NY
Imbrici P, Tricarico D, Mangiatordi GF, Nicolotti O, Lograno MD, Conte D, Liantonio A (2017) Pharmacovigilance database search discloses ClC-K channels as a novel target of the AT1 receptor blockers valsartan and olmesartan. Br J Pharmacol 174:1972–1983
Fermini B, Hancox JC, Abi-Gerges N et al (2016) A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen 21:1–11
Fahlke C, Fischer M (2010) Physiology and pathophysiology of ClC-K/barttin channels. Front Physiol 1:155
Birkenhäger R, Otto E, Schürmann MJ et al (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314
Simon DB, Bindra RS, Mansfield TA et al (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet 17:171–178
Imbrici P, Liantonio A, Gradogna A, Pusch M, Camerino DC (2014) Targeting kidney CLC-K channels: pharmacological profile in a human cell line versus Xenopus oocytes. Biochim Biophys Acta 1838:2484–2491
Loudon KW, Fry AC (2014) The renal channelopathies. Ann Clin Biochem 51:441–458
Zieg J, Gonsorcikova L, Landau D (2016) Current views on the diagnosis and management of hypokalaemia in children. Acta Paediatr 105:762–772
Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D (2014) Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect 2(1):e00028
Pitts PJ, Louet HL, Moride Y, Conti RM (2016) 21st century pharmacovigilance: efforts, roles, and responsibilities. Lancet Oncol 17:e486–e492
Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483–486
Reinalter SC, Jeck N, Peters M, Seyberth HW (2004) Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand 181:513–521
Lupoli S, Salvi E, Barcella M, Barlassina C (2015) Pharmacogenomics considerations in the control of hypertension. Pharmacogenomics 16:1951–1964
Lazelle RA, McCully BH, Terker AS, Himmerkus N, Blankenstein KI, Mutig K, Bleich M, Bachmann S, Yang C-L, Ellison DH (2016) Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension. J Am Soc Nephrol 27:1456–1464
Chen Y-S, Fang H-C, Chou K-J, Lee P-T, Hsu C-Y, Huang W-C, Chung H-M, Chen C-L (2009) Gentamicin-induced Bartter-like syndrome. Am J Kidney Dis 54:1158–1161
Zietse R, Zoutendijk R, Hoorn EJ (2009) Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 5:193–202
Liantonio A, Picollo A, Babini E, Carbonara G, Fracchiolla G, Loiodice F, Tortorella V, Pusch M, Camerino DC (2006) Activation and inhibition of kidney CLC-K chloride channels by fenamates. Mol Pharmacol 69:165–173
Liantonio A, Picollo A, Carbonara G et al (2008) Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands. Proc Natl Acad Sci U S A 105:1369–1373
Liantonio A, Imbrici P, Camerino GM et al (2016) Kidney CLC-K chloride channels inhibitors: structure-based studies and efficacy in hypertension and associated CLC-K polymorphisms. J Hypertens 34:981–992
Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R (2002) X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity. Nature 415:287–294
Gradogna A, Imbrici P, Zifarelli G, Liantonio A, Camerino DC, Pusch M (2014) I–J loop involvement in the pharmacological profile of CLC-K channels expressed in Xenopus oocytes. Biochim Biophys Acta 1838:2745–2756
Small-molecule drug discovery suite 2015-3: Schrödinger suite 2015-3 induced fit docking protocol; glide version 6.8, Schrödinger, LLC, New York, NY, 2015; Prime version 4.1, Schrödinger, LLC, New York, NY, 2015
Cheng C-J, Rodan AR, Huang C-L (2017) Emerging targets of diuretic therapy. Clin Pharmacol Ther 102:420–435
Windley MJ, Abi-Gerges N, Fermini B, Hancox JC, Vandenberg JI, Hill AP (2017) Measuring kinetics and potency of hERG block for CiPA. J Pharmacol Toxicol Methods 87:99–107
O’Hara T, Virág L, Varró A, Rudy Y (2011) Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7:e1002061
Cavero I, Holzgrefe H (2015) CiPA: ongoing testing, future qualification procedures, and pending issues. J Pharmacol Toxicol Methods 76:27–37
Li Z, Dutta S, Sheng J, Tran PN, Wu W, Chang K, Mdluli T, Strauss DG, Colatsky T (2017) Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-à-go-go-related gene) Channel-drug binding kinetics and multichannel pharmacology. Circ Arrhythm Electrophysiol 10:e004628
McCallum L, Lip S, Padmanabhan S (2015) The hidden hand of chloride in hypertension. Pflugers Arch 467:595–603
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Imbrici, P., Nicolotti, O., Leonetti, F., Conte, D., Liantonio, A. (2018). Ion Channels in Drug Discovery and Safety Pharmacology. In: Nicolotti, O. (eds) Computational Toxicology. Methods in Molecular Biology, vol 1800. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7899-1_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7899-1_15
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7898-4
Online ISBN: 978-1-4939-7899-1
eBook Packages: Springer Protocols